The Lancet publishes a review article on neurofibromatosis research in China by Li Qingfeng's team from the Ninth Affiliated Hospital

Recently, LANCET NEUROLOGY (IF 59.

Due to the low awareness of NF1 among the public, the scientific community has not paid enough attention to it.

For a long time, NF1, as a rare intractable disease, has long been a pain for patients and a difficulty for doctors

Professor Li Qingfeng led the NF1 team to establish the first pilot site for neurofibromatosis drug treatment in China in Boao, Hainan, where neurofibromatosis patients who meet the indications for drug treatment receive "sympathetic medication"

In 2021, China's first expert consensus on clinical diagnosis and treatment of NF1 (2021), led by Professor Li Qingfeng from the Ninth Affiliated Hospital, with Associate Professor Wang Zhichao as the first author, and experts and scholars from multiple disciplines, will be published in the Chinese Journal of Rehabilitation and Reconstruction Surgery.

Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder that typically presents as multiple café-au-lait spots and neurofibromas on the skin, or plexiform neurofibromas involving the main nerves, often with There are skeletal deformities, learning disabilities, central nervous system tumors and other problems, which lead to social barriers in patients

The Department of Rehabilitation and Rehabilitation of the Affiliated Ninth People's Hospital is one of the largest diagnosis and treatment centers for neurofibromatosis type 1 in China.

Paper link: